ACST | tickerfilter.com

Fundamental analysis

25%

Profitability 33%

Dept financing 23%

Liquidity 50%

Performance 13%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.94%

1 Month

-2.96%

3 Months

-2.93%

6 Months

-22.94%

1 Year

26.12%

2 Year

-46.81%

Key data

Stock price

$2.64

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$1.72 - $3.59

52 WEEK CHANGE

$0.25

MARKET CAP

26.566 M

YIELD

N/A

SHARES OUTSTANDING

10.140 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.45

PUBLIC FLOAT

AVERAGE 10 VOLUME

$11,009

AVERAGE 30 VOLUME

$11,643

Company detail

CEO: Janelle D'Alvise
Region: US
Website: https://www.acastipharma.com/
Employees: 33
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.

ACST - Acasti Pharma Inc - Ordinary Shares - Class A